[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344153-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344153-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","repurposing-fda-approved-drugs-targeting-fzd10-in-nasopharyngeal-carcinoma-insights-from-molecular-dynamics-simulations-and-experimental-validation","Repurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma - insights from molecular dynamics simulations and experimental validation","","Wnt signaling and its Frizzled receptor FZD10 are implicated in nasopharyngeal carcinoma progression and recurrence, motivating development of therapies that directly target FZD10. Human FZD10 structure was built via homology modeling and validated through Ramachandran plot and ProQ. Virtual screening of 1,094 FDA-approved drugs produced 17 candidate FZD10 inhibitors, with prazosin, rilpivirine, doxazosin, and nicergoline showing notable cytotoxicity. Molecular dynamics and binding-energy analyses supported stable drug binding, indicating repurposed candidates for targeted NPC treatment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/repurposing-fda-approved-drugs-targeting-fzd10-in-nasopharyngeal-carcinoma-insights-from-molecular-dynamics-simulations-and-experimental-validation/344153/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/repurposing-fda-approved-drugs-targeting-fzd10-in-nasopharyngeal-carcinoma-insights-from-molecular-dynamics-simulations-and-experimental-validation/344153.png","ImageObject",300,407,{"name":42,"@type":43},"Clementine","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main therapeutic target in this study?","Question",{"text":63,"@type":64},"The study targets FZD10, a Frizzled receptor involved in Wnt signaling associated with cancer development and recurrence.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the FDA-approved drugs screened for potential FZD10 inhibition?",{"text":68,"@type":64},"The authors performed virtual screening of 1,094 FDA-approved drugs to identify 17 potential inhibitors, followed by assessment of cytotoxicity against nasopharyngeal carcinoma cells.",{"name":70,"@type":61,"acceptedAnswer":71},"What validated the stability of drug binding to FZD10?",{"text":72,"@type":64},"Further molecular dynamics simulations and binding energy analyses were used to confirm stable binding of the selected drugs to FZD10.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344153,1790193406,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nRepurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma: insights from molecular dynamics simulations and experimental validation  \nChawalit Ngernsombat1,2, Utid Suriya3, Pongphol Prattapong1,3, Kanika Verma4,5, Thanyada Rungrotmongkol4,5, Thananya Soonkum6, Sakonwan Kuhaudomlarp3 & Tavan Janvilisri3􀀍  \nWnt signaling is a critical pathway implicated in cancer development, with Frizzled proteins, particularly FZD10, playing key roles in tumorigenesis and recurrence. This study focuses on the potential of repurposed FDA-approved drugs targeting FZD10 as a therapeutic strategy for nasopharyngeal carcinoma (NPC). The tertiary structure of human FZD10 was constructed using homology modeling, validated by Ramachandran plot and ProQ analysis. Virtual screening of 1,094 FDA-approved drugs identified 17 potential inhibitors, with prazosin, rilpivirine, doxazosin, and nicergoline demonstrating significant cytotoxicity against NPC cells. Further molecular dynamics simulations and binding energy analyses confirmed the stable binding of these drugs to FZD10. The results suggest that these repurposed drugs could serve as promising candidates for targeted NPC therapy, warranting further investigation.  \nKeywords Drug repurposing, Wnt signaling, Nasopharyngeal carcinoma  \nWnt signaling is a vital pathway involved in embryonic development and adult tissue regeneration1. It comprises two main pathways: the canonical and non-canonical Wnt pathways, both requiring Wnt ligands to bind to membrane receptor proteins to activate signal transduction. Interestingly, Wnt signaling has been extensively investigated in the development and progression of various cancers, such as gastric cancer, lung cancer, colorectal cancer, leukemia, bladder cancer, and nasopharyngeal cancer2–6. The Frizzled (FZD) protein family, which serves as membrane receptors in the Wnt signaling pathway, has implications for cancer development. For instance, FZD1 is diagnostically relevant in clear cell renal cell carcinoma7. FZD7 is upregulated in gastric and esophageal squamous cell carcinoma, facilitating β-catenin nuclear translocation, and activation of the WNT/β-catenin signaling pathway, including the epithelial-mesenchymal transition (EMT) process8,9. Meanwhile, FZD8’s high expression is crucial for the proliferation and metastasis of renal cell carcinoma10. FZD10, a member of the Frizzled protein family, has gained attention for its role in cancer. Initially identified as upregulated in cervical and colon cancers, FZD10 is absent in healthy adult tissues but becomes upregulated in the late stages of colon tumor progression11, 12. Our previous transcriptomic analysis identified enhanced Wnt signaling in recurrent nasopharyngeal carcinoma (NPC) tissues, with FZD10 significantly upregulated and correlated with NPC recurrence13. This discovery led to our focus on targeting FZD10 for NPC therapy. Inhibiting the Wnt signaling pathway is a key strategy for cancer therapy, with several FZD-targeted therapeutic drugs in development. For example, OMP18R5, a monoclonal antibody that binds to and blocks FZD function, has shown efficacy in  \n1Graduate Program in Molecular Medicine, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.  \n2Division of Biochemistry, Department of Preclinical Science, Faculty of Medicine, Thammasat University, Pathumthani 12120, Thailand. 3Department of Biochemistry, Faculty of Science, Mahidol University, 272 Rama VI Road, Thung Phayathai, Ratchathewi, Bangkok 10400, Thailand. 4Program in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok 10330, Thailand. 5Center of Excellence in Structural and Computational Biology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok 10330, Thailand. 6Frontier Research Facility—Central Instrument Facility Unit, Office of the President, Mahido","cbCaigMdZIgMmUk8","https://ap.wps.com/l/cbCaigMdZIgMmUk8","pdf",2906092,16,"English","# Background\n## Wnt signaling and FZD10 in cancer\n## Current therapeutic options and need for targeted therapy\n# Methods and in silico screening\n## Homology modeling and structure validation\n## Virtual screening of FDA-approved drugs\n# Molecular validation and results\n## Molecular dynamics and binding energy analyses\n## Candidate drugs with cytotoxicity in NPC cells\n# Conclusions","[{\"question\":\"What is the main therapeutic target in this study?\",\"answer\":\"The study targets FZD10, a Frizzled receptor involved in Wnt signaling associated with cancer development and recurrence.\"},{\"question\":\"How were the FDA-approved drugs screened for potential FZD10 inhibition?\",\"answer\":\"The authors performed virtual screening of 1,094 FDA-approved drugs to identify 17 potential inhibitors, followed by assessment of cytotoxicity against nasopharyngeal carcinoma cells.\"},{\"question\":\"What validated the stability of drug binding to FZD10?\",\"answer\":\"Further molecular dynamics simulations and binding energy analyses were used to confirm stable binding of the selected drugs to FZD10.\"}]","Repurposing FDA-approved drugs targeting FZD10 in nasopharyngeal carcinoma - insights from molecular dynamics simulations and experimental validation | PDF",1790053126,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9660e298e4e294599084db6965ced5f.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb9be0f21b32f0e7214c70d6887ad36b.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e6353a72160461bab6fcf2304f3c1e93.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfd85731ba56fdd74d2753f77f0839bf.webp",980,1287]